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Abstract The pharmacokinetics of oral dexniguldipine,
a new multidrug-resistance-modifying agent under clin-
ical evaluation, and its pyridine metabolite M-1 were
determined in plasma, tumor, and renal tissue in Wag/
Rij rats bearing a multidrug-resistant CC531 colon
adenocarcinoma tumor under the renal capsule. The
pharmacokinetics were studied in four experiments.
After a single administration of dexniguldipine (30 mg/
kg), tumors and kidneys were collected after 5 (experi-
ment 1), 24 (experiment 2), and 48 h (experiment 3). In
the fourth experiment, dexniguldipine was given once
daily for 3 consecutive days at a dose of 30 mg/kg. In all
experiments, plasma samples were collected at regular
intervals. The concentrations of dexniguldipine and M-1
could be determined in plasma in most of the rats at up
to 32 h after drug administration. The area under the
curve (AUC) of dexniguldipine and M-1 varied by
a factor of 2–6 in the four experiments. High tumor-
tissue concentrations of dexniguldipine were observed.
The concentrations were highest in the multiple-dose
experiment (2014  1005 ng/g tissue). High degrees of
correlation (>0.8) were established between the concen-
trations of dexniguldipine measured in plasma and
tumor as well as renal tissue. Overall, tumor-tissue
concentrations of M-1 comprised one-third of the dex-
niguldipine concentrations measured.
Key words Dexniguldipine á Pharmacokinetics á
Multidrug-resistance chemosensitizer
Introduction
Dexniguldipine is the ()) enantiomer of niguldipine, a
dihydropyridine derivative. In in vitro studies,
dexniguldipine has been found to bind to P-glycoprotein
(P-gp) and to enhance the cytotoxicity of chemothera-
peutic agents such as doxorubicin and etoposide in
several cell lines resistant to these agents [3–5]. The
synergistic eect may well be associated with reversal of
multidrug resistance (MDR) related to the activity of
P-gp. Also, the pyridine metabolite M-1 has demon-
strated pharmacologic activity [3–5, 8]. Dexniguldipine
is extensively metabolized by the cytochrome P450 sys-
tem and, most likely, by CYP (CYP 3A).
In addition, other in vitro studies have revealed that
dexniguldipine itself has potent and selective cytotoxic
activity against several tumor cell lines. The mechanism
of cytotoxic action has not been fully elucidated, but
interaction with protein kinase C and other parts of the
intracellular signal-transduction pathway have been
proposed [2, 12].
Many MDR-modifying agents have been applied in
the clinic, such as verapamil, cyclosporin A, quinidine,
and tamoxifen, among others [9, 11, 13]. The results
obtained with verapamil have revealed serious cardio-
vascular side eects at levels of exposure that are pre-
sumably insucient to achieve MDR reversal [10]. In
addition, the lack of information about tumor-tissue
concentrations of the MDR modifier has limited the
optimal design of clinical studies with an MDR modifier
and a P-gp-dependent anticancer agent [6, 17]. The af-
finity of dexniguldipine for the calcium-channel receptor
site is relatively low. This enables clinical administration
of high doses of the drug. However, the resulting
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concentration range of the drug in tumor tissues has not
been established. At present, dexniguldipine in combi-
nation with anticancer agents is undergoing phase I/II
clinical testing, for example, in small-cell lung cancer.
The aim of the present study was to explore the
pharmacokinetics of dexniguldipine and its pyridine
metabolite M-1 in the plasma, tumor, and renal tissue of
Wag/Rij rats bearing an intrinsic MDR CC531 colon
adenocarcinoma as a solid tumor under the renal cap-
sule [1, 15].
Materials and methods
Experiments were approved by the Animals Ethics Board of the
University of Rotterdam.
Assay of dexniguldipine and M-1 in plasma,
tumor, and renal tissue
Apparatus
Dexniguldipine and M-1 were determined in plasma, tumor, and
renal tissue using an automated reverse-phase isocratic high-per-
formance liquid chromatography (HPLC) assay with UV detection
at 230 nm. A model 710B WISP autosampler and a model M510
pump were used (Waters Associates, Milford, Mess. USA). The
detector was a UV2000 device (Spectra Physics, San Jose, Calif.
USA). The data were processed with a Shimadzu CR3A integrator
(Shimadzu Corporation, Kyoto, Japan). The column was a Shan-
don Hypersyl CPS column (3 lm, 150 ´ 4.6 mm; LC Service,
Emmen, The Netherlands). The eluent consisted of 5 mM phos-
phate buer (pH 7.5) with 60% acetonitrile. The flow rate was
1.5 ml/min and the column temperature was 40 °C. A volume of
100 ll was injected into the HPLC system.
Chemicals
Dexniguldipine hydrochloride (B8509-035, batch 292-349), me-
tabolite M-1 {B8909-008, batch U1 29/071; chemical name 3-ace-
tyl-2,6-dimethyl-4-nitrophenyl-5-[5-(4,4-diphenyl-1-piperidinyl)-
pentanoyl] pyridine fumarate}, and the internal standard for the
assay (B 9003-001, batch Zi 04/106) were obtained from Byk Gu-
lden (Konstanz, Germany). All other chemicals were obtained from
Baker (Deventer, The Netherlands) and were of analytical grade.
Plasma-sample preparation
A volume of 150 ll plasma was collected, to which 50 ll of a 2000-
ng/ml solution of internal standard (B 9003-001, batch Zi 04/106)
in methanol was added. A volume of 800 ll deionized Milli-Q
water was added, and the solution was mixed on a whirl mixer for
15 s. For extraction a volume of 7 ml dichloromethane (DCM)/
hexane/isobutylalcohol (40:60:0.5, by vol.) was added. The liquid
was mixed for 30 min on a whirl mixer and subsequently centri-
fuged for 5 min at 4000 g. The organic layer was collected and
evaporated to dryness at 50 °C under vacuum. The residue was
reconstituted in 150 ll eluent. Calibration curves were constructed
at up to 2000 ng/ml. The recovery of dexniguldipine, M-1, and the
internal standard was determined relative to the direct injection of
the individual dissolved compounds.
Tumor-tissue extraction
Tumor tissue was homogenized with a Turrax homogenizer (Boom,
Meppel) in 1 ml Milli-Q water. The Turrax was flushed twice with
250 ll Milli-Q water. A 50-ll volume of a 2000-ng/ml internal
standard solution in methanol was added. Subsequently, a 7-ml
volume of DCM/hexane/isobutylalcohol (40:60:0.5 by vol.) was
added and the mixture was vortexed for 30 min. Thereafter the
mixture was centrifuged for 5 min at 4000 g. The organic layer was
collected and evaporated to dryness at 50 °C under vacuum. The
residue was reconstituted in 150 ll eluent. The recovery of
dexniguldipine, M-1, and the internal standard was determined rel-
ative to the direct injection of the individual dissolved compounds.
Construction of calibration curves at up to 500 ng in tumor tissue
Dexniguldipine hydrochloride (B8509-035, batch 292-349) and
B8909-008 (M-1, batch U1 29/071) were added to clean test tubes
and the samples were evaporated under vacuum. Approximately
100 mg tumor tissue was added. Subsequently the procedure was
carried out as outlined above.
Tumor model and in vivo experiments
Solid tumors of the CC531 colon adenocarcinoma tumor model
were used according to a previously described method [7, 15].
Tumors of the intrinsic MDR cell line (CC531) were grown in
donor Wag/Rij rats. Tumor particles of 6–7 mg were prepared and
implanted under the renal capsule of both kidneys of the rats
(subrenal capsule model). In all pharmacokinetics experiments, two
particles were implanted per kidney. For each experiment (i.e., 5-,
24-, 48-h, and repeated administration) a new tumor batch was
grown in donor rats. In all rats the right jugular vein was cannu-
lated in the pharmacokinetics experiments for blood sampling at
regular intervals. The experiments were started on day 1 with tu-
mor implantation. The rats were cannulated, after full recovery, on
day 3 or 4. During the experiments, diethyl ether anesthesia was
applied. After termination of the experiments, rats were killed by
cervical dislocation.
Pharmacokinetics experiments
An oral solution of 30 mg/kg dexniguldipine (1.5 ml/kg) was given
through a thin metal oral cannula of 23 gauge on day 8 (single
administration) or days 8–10 (repeated administration) after tumor
implantation. Eight rats per treatment group were used. The so-
lution consisted of an undiluted 2% dexniguldipine microemulsion
(batch LSc 1974). The rats were given no food the night prior to the
experiment. They had free access to drinking water. Blood samples
were collected for up to 5 (5-h experiment), 24 (24-h experiment), or
48 (48-h experiment). The time points were 0, 10, 20, 30, 60, and
120 min and 4, 6, 10, 24, 32, and 48 h. In the 5- and 24-h experi-
ments the sampling times ended at 5 and 24 h, respectively. Tumors
and kidneys were collected immediately at the end of the sampling
period. In the multiple-dose experiment, peak (2 h after drug in-
take) and trough (immediately prior to the next drug intake) blood
samples were collected. Tumors and kidneys were collected at 5 h
after administration of the final dose on day 10. The area under the
curve (AUC) was calculated using the lin-log trapezoidal method in
all experiments. The Pearson correlation coecient was calculated
were appropriate.
Results
Assay of dexniguldipine and M-1 in plasma,
tumor, and renal tissue
Results of the analysis of dexniguldipine and M-1 plasma
Calibration curves were linear up to the studied con-
centration of 2000 ng/ml. Correlation coecients were
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better than 0.999. The lower limit of quantitation (LLQ)
of dexniguldipine and M-1 was 25 ng/ml. The between-
run coecient of variation (%CV) at the LLQ was
15.1% for dexniguldipine and 24.7% for M-1. At almost
all concentrations higher than the LLQ the %CV was
around 5% or lower.
Results of the tumor-tissue extraction
Calibration curves were linear up to the studied con-
centration of 500 ng. The correlation coecients were
>0.999. The LLQ of dexniguldipine and M-1 in tumor
and renal tissue was 25 ng/g.
Pharmacokinetic experiments
In the 5-h experiment, seven of the eight rats were
evaluable for plasma kinetics of dexniguldipine and M-1
and all rats were evaluable for tumor- and renal-tissue
uptake. The plasma AUCs determined for the 48-h ex-
periment are given in Fig. 1. The AUC data are sum-
marized in Table 1. The AUC of M-1 was always lower
than that of the parent drug (Table 1). The concentra-
tion-time curves generated for the 48-h experiment re-
veal that the plasma concentration at 48 h could be
determined in only one of the rats. In almost all rats the
concentration-time curves could be determined at up to
32 h after administration. The AUC0–48 h was calculated
up to the latest measurable data point. The mean plasma
concentration-time profiles obtained for the 24- and
48-h experiments were superimposable, which illustrates
that the pharmacokinetics are reproducible (Fig. 2).
In the repeated-administration experiment, only lim-
ited plasma-kinetics data became available. Three
cannulas became plugged and one rat was killed on day
1 of the 3-day experiment because of toxicity (reduced
muscle tone, pilo erection, low blood pressure). The
limited plasma-concentration data do not show major
dierences in the kinetics determined on days 1, 2, and 3.
The tumor concentrations of dexniguldipine and M-1
measured in the outlined experiments are given in
Table 2. The concentrations of M-1 were substantially
lower than those of the parent drug.
The concentrations of dexniguldipine were higher in
renal tissue than in tumor tissue (Table 2). Also, the M1
concentrations in renal tissue were on the order of 30%
of the dexniguldipine concentrations, which resembles
the relationship found in tumor tissue (data not shown).
Fig. 1 Plasma concentration-time curves generated for dexniguldi-
pine for up to 48 h in 7 Wag/Rij rats after a single oral
administration of 30 mg/kg dexniguldipine. Data recorded for rat
8 were not evaluable
Table 1 AUC data recorded
for dexniguldipine and M-1 in
Wag/Rij rats after single or re-
peated oral administration of a
dose of 30 mg/kg dexniguldipi-
nea (Dex Dexniguldipine, NE
not evaluable)







Dex M-1 Dex M-1 Dex M-1
Mean 0.67 0.16 2.17 0.64 2.49 0.54
SD 0.80 0.15 1.03 0.34 0.64 0.43
Range 0.22–2.47 0.03–0.48 1.15–4.31 0.12–1.26 1.76–3.49 0.16–1.19
aThe AUC data (n = 7) were calculated in all experiments up to the latest measured time point. In the
48-h experiment the AUC was determined up to the latest measurable concentration, which was
detected at 31.7 h in all except one rat (11.2 h in rat 6)
Fig. 2 Mean plasma concentration-time curves generated for the
24- and 48-h experiments, combined with the mean tumor
concentrations obtained in the 5-, 24-, and 48-h experiments
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The order of magnitude of the renal concentrations re-
corded in the individual experiments was the same as
that found in tumor tissue. The decline in the plasma
concentration-time curves generated for the 24- and 48-h
experiments paralleled the decline in the tumor-tissue
concentrations of dexniguldipine, which illustrates the
close relationship between the plasma kinetics and the
tumor kinetics of dexniguldipine (Fig. 2). In this figure
the tumor concentrations measured in the 5-, 24-; and
48-h experiments were combined for the construction of
a concentration-time curve. Furthermore, high correla-
tion coecients were found between the tumor-tissue
concentrations measured at the end of the experiment
and the plasma AUC values obtained in the 5- (R=0.98,
n=7) and 24-h experiments (R=0.84, n=7; Fig. 3). The
relationship between the tumor-tissue concentration and
AUC0–48 was not calculated because the AUC0–48 value
could not be determined in most of the rats, as is out-
lined above.
In addition, high correlation coecients were found
between tumor- and renal-tissue concentrations in all
experiments (R values of at least 0.92). The tumor
weights recorded in the four experiments varied and
were 63  19 (5 h), 57  15 (24 h), 131  42 (48 h),
and 81  29 mg (repeated administration).
Discussion
The present data describe the plasma, tumor, and renal-
tissue kinetics of dexniguldipine and its metabolite M-1
after single or repeated oral administration of 30 mg/kg
dexniguldipine to tumor-bearing Wag/Rij rats. The
concentrations of dexniguldipine and metabolite M-1
were determined in tumor tissue at 5, 24, and 48 h to
evaluate the uptake kinetics in tumor tissue. In addition,
the tumor concentrations were determined after 3 days
of drug administration.
The plasma concentration-time curves generated for
the 5-h experiment showed only a moderate decline. The
kinetics in plasma were highly variable. In the 24-h ex-
periment the AUC ranged from 1.15 to 4.31 lg h ml)1.
In addition, the time to maximal plasma concentration
(Tmax) was highly variable (Fig. 1). Also, a study in
humans has revealed that the pharmacokinetics are
highly variable [14]. The elimination phase in the 48-h
experiment was not long enough to enable calculation of
the total AUC.
In the experiment involving repeated administration,
limited plasma data became available due to plugging of
three of the cannulas during the experiment. The plas-
ma-concentration data recorded for the four evaluable
rats revealed that the concentrations did not further
increase after 2 days of dosing, indicating that near-
steady state had been reached. The administration once
daily of 30 mg/kg dexniguldipine for 3 subsequent days
was feasible except in one rat. No significant cumulative
toxicity in the remaining animals was observed. A pre-
vious pilot experiment revealed that this dose was the
highest feasible dose upon repeated administration in
this model (data not shown).
The tumor concentrations of dexniguldipine and M-1
also showed wide variation (Table 2). It is unlikely that
this variation would be due to dierences in the distri-
bution kinetics of dexniguldipine, considering the high
degrees of correlation found between AUC values and
tumor concentrations of dexniguldipine. The concen-
trations of the parent drug and M-1 were highest after
repeated administration of the former. The high degrees
of correlation found between plasma and tumor-tissue
concentrations enable the prediction of tumor concen-
trations using plasma samples in this in vivo model. The
high variability of the plasma concentrations may be
attributable to variation between rats in the bioavail-
ability of dexniguldipine.
High degrees of correlation were found between tu-
mor- and renal-tissue concentrations of dexniguldipine.
The renal-tissue concentrations were always a factor of
1.5–4 higher than the tumor-tissue concentrations, de-
pending on the sampling time (Table 2). Dexniguldipine
is a dihydropyridine derivative. This class of drugs is
known to be extensively distributed in tissue. Dierences
Fig. 3 Correlation between the tumor-tissue concentrations of
dexniguldipine and the AUC0–5 determined in the 5-h experiment.
The correlation coecient was also calculated without the extreme
observation (*)
Table 2 Concentrations of dexniguldipine and metabolite M1
measured in tumor and normal renal tissue of rats at selected times
after the administration of a single oral dose of 30 mg/kg dexni-
guldipine. Concentrations are expressed as mean values  SD
(n = 7) in ng/g tissue a(Dex Dexniguldipine)
5 hr 24 hr 48 hr
Dex in tumor 1463  1470 595  404 386  330
M1 in tumor 398  293 262  182 146  107
Dex in renal tissue 2707  1028 2632  1811 463  444
aTumor tissue was obtained after the growth of implanted particles
of CC531 adenocarcinoma in a renal subcapsular assay (see
Materials and methods)
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in lipophilicity between tissues, e.g., renal and tumor
tissue, may therefore contribute to the observation of
dierences in tissue concentration after exposure to
dexniguldipine, in particular at steady state. The ratio of
dexniguldipine to M1 was constant in all experiments.
The tumor weights showed variation between the
experiments. The mean tumor weight measured in the
48-h experiment was clearly higher than that measured
in the other experiments, which may have been due to
tumor-batch dierences. As a consequence, tumor
growth-inhibition experiments should be carried out
using the same tumor batch.
The in vitro results reported for the MDR-modifying
eect of dexniguldipine revealed that dexniguldipine was
highly active at a concentration as low as 50 ng/ml [16].
In that experiment the same CC531 cell line was used. It
is hazardous to extrapolate the results of in vitro studies
to in vivo tumor models. However, considering the very
high tumor-tissue concentrations of dexniguldipine
measured in vivo, it may be anticipated that these con-
centrations are high enough to reverse MDR in vivo.
Results of the pharmacodynamics study of dexniguldi-
pine and epidoxorubicin in this model reveal a moder-
ately but significantly synergistic antitumor eect [16].
In the present study, high concentrations were
achieved in intrinsically MDR solid-tumor tissue im-
planted under the renal capsule of rats after single and
multiple oral dosing of the MDR-modifying drug dex-
niguldipine. In addition, the high degrees of correlation
found between plasma and tumor-tissue concentrations
enable the prediction of tumor concentrations in this
model by simple measurement of plasma concentrations.
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